- Cited — Sandoz Limited v Bristol-Myers Squibb Holdings Ireland Unlimited Company 2023-05-04
“…In Warner-Lambert Co LLC v Generics (UK) Ltd [2018] UKSC 56, [2019] Bus LR 360 the patent contained second medical use claims in Swiss form of a known pharmaceutical, pregabalin. Claim 1 claimed the use of pregabalin to…”
- Cited — Dr Reddy's Laboratories (UK) Limited & Ors v Warner-Lambert Company LLC 2023-02-01
“…ies permission to argue the infringement issues. On 14 November 2018 the Supreme Court handed down judgment dismissing the appeal and allowing the cross-appeal [2018] UKSC 56, [2019] Bus LR 360 (“Warner-Lambert SC”). In brief summary, the majority of the Supreme Court agreed with the lower courts that claims 1 and 3 (and therefore c…”
- Cited — Dr Reddy's Laboratories (UK) Limited & Ors v Warner-Lambert Company LLC 2023-02-01
“… He submitted that a case under section 60(1)(b) had not been advanced in the action which went to the Supreme Court (Warner-Lambert Co LLC v Generics (UK) Ltd [2018] UKSC 56, [2019] 3 All ER 95), that in any event what was said about infringement in the Supreme Court was obiter even on issues on which all the judges agreed, and tha…”
- Cited — InterDigital Technology Corporation & Ors v Lenovo Group Ltd & Ors 2023-01-19
“… of patent law, that the extent of the monopoly defined by the claims should correspond to the technical contribution to the art (citing Warner-Lambert v Mylan [2018] UKSC 56 at paragraph 17).…”
- Cited — Alcon Research LLC & Anor. v Pharmathen SA & Anor. 2022-06-28
“…[2018] UKSC 56, [2019] Bus LR 360 at [36]: “the specification must disclose some reason for supposing that the implied assertion of efficacy in the claim is true”.…”
- Followed — Neurim Pharmaceuticals (1991) Limited & Anor. v Generics (UK) Limited & Anor. 2022-05-27
“…[2018] UKSC 56, [2019] Bus LR 360 at [36]-[37] as follows:…”
- Cited — Illumina Cambridge Limited v Latvia MGI Tech Sia 2021-12-17
“… does not dispute that, if plausibility is required, the criterion for plausibility is that stated by Lord Sumption in Warner-Lambert Co LLC v Generics (UK) Ltd[2018] UKSC 56, [2019] Bus LR 360 at [36]: “the specification must disclose some reason for supposing that the implied assertion of efficacy in the claim is true”. As Lord Su…”
- Cited — L'Oreal (UK) Ltd & Anor v Liqwd Inc & Anor 2019-11-18
“…Before us counsel for Olaplex placed some reliance upon the line of cases culminating in Generics (UK) Ltd v Warner-Lambert Co LLC [2018] UKSC 56, [2019] Bus LR 360 in which courts have rejected applications made by patentees to amend the claims of patents after trial on the ground of abuse of process. I…”